These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 17524530)

  • 1. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP.
    Cao J; Chen D; Xu W; Chen T; Xu S; Luo J; Zhao Q; Liu B; Wang D; Zhang X; Shan Y; Yin Y
    Vaccine; 2007 Jun; 25(27):4996-5005. PubMed ID: 17524530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4(+) T lymphocytes mediated protection against invasive pneumococcal infection induced by mucosal immunization with ClpP and CbpA.
    Cao J; Gong Y; Li D; Yin N; Chen T; Xu W; Zhang X; Yin Y
    Vaccine; 2009 May; 27(21):2838-44. PubMed ID: 19366577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide.
    Csordas FC; Perciani CT; Darrieux M; Gonçalves VM; Cabrera-Crespo J; Takagi M; Sbrogio-Almeida ME; Leite LC; Tanizaki MM
    Vaccine; 2008 Jun; 26(23):2925-9. PubMed ID: 18440673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced protective immunity against pneumococcal infection with PspA DNA and protein.
    Moore QC; Bosarge JR; Quin LR; McDaniel LS
    Vaccine; 2006 Jul; 24(29-30):5755-61. PubMed ID: 16759765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genetic background of Streptococcus pneumoniae affects protection in mice immunized with PspA.
    He X; McDaniel LS
    FEMS Microbiol Lett; 2007 Apr; 269(2):189-95. PubMed ID: 17355599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to the pneumococcal surface protein A, PspA, can be produced in splenectomized and can protect splenectomized mice from infection with Streptococcus pneumoniae.
    Coats MT; Benjamin WH; Hollingshead SK; Briles DE
    Vaccine; 2005 Jul; 23(33):4257-62. PubMed ID: 16005736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A.
    Hotomi M; Kono M; Hollingshead SK; Briles DE; Yamanaka N
    Adv Otorhinolaryngol; 2011; 72():121-5. PubMed ID: 21865708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct approaches to investigate the importance of the murine 4-1BB 4-1BBL interaction in the antibody response to Streptococcus pneumoniae.
    Moens L; Jeurissen A; Mittler RS; Wuyts G; Michiels G; Boon L; Ceuppens JL; Bossuyt X
    J Leukoc Biol; 2007 Sep; 82(3):638-44. PubMed ID: 17550973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.
    Briles DE; Hollingshead SK; King J; Swift A; Braun PA; Park MK; Ferguson LM; Nahm MH; Nabors GS
    J Infect Dis; 2000 Dec; 182(6):1694-701. PubMed ID: 11069242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against pneumococcal infection elicited by immunization with multiple pneumococcal heat shock proteins.
    Cao J; Zhang X; Gong Y; Zhang Y; Cui Y; Lai X; Yin Y; Li M; Li D; Zhang L
    Vaccine; 2013 Aug; 31(35):3564-71. PubMed ID: 23727004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production.
    Ferreira DM; Darrieux M; Oliveira ML; Leite LC; Miyaji EN
    Clin Vaccine Immunol; 2008 Mar; 15(3):499-505. PubMed ID: 18184825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A).
    Ferreira DM; Oliveira ML; Moreno AT; Ho PL; Briles DE; Miyaji EN
    Microb Pathog; 2010 Jun; 48(6):205-13. PubMed ID: 20206678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae.
    Ogunniyi AD; Grabowicz M; Briles DE; Cook J; Paton JC
    Infect Immun; 2007 Jan; 75(1):350-7. PubMed ID: 17088353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection.
    Hanniffy SB; Carter AT; Hitchin E; Wells JM
    J Infect Dis; 2007 Jan; 195(2):185-93. PubMed ID: 17191163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular dissection of antibody responses against pneumococcal surface protein A: evidence for diverse DH-less heavy chain gene usage and avidity maturation.
    Rohatgi S; Dutta D; Tahir S; Sehgal D
    J Immunol; 2009 May; 182(9):5570-85. PubMed ID: 19380805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae.
    McDaniel LS; Loechel F; Benedict C; Greenway T; Briles DE; Conry RM; Curiel DT
    Gene Ther; 1997 Apr; 4(4):375-7. PubMed ID: 9176525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.